Objective: To assess whether patients who received a PKG analysis in routine care featured improved PD symptom scores over time using the PKG central repository.

Background: The Parkinson’s Kinetigraph (PKG) is a commercially available medical device that objectively measures treatable Parkinson’s disease (PD) symptoms continuously in daily living. Collected symptom scores – bradykinesia [BKS], Dyskinesia [DKS], Fluctuation Score [FDS] – have been validated and correlate with PD reference standard instruments (UPDRS, AIMS, Patient Diaries). The PKG is used globally – in Europe, AsiaPacific, and the USA. There is a deidentified central repository of all PKG reports.

Methods: PD patients who had 2+ PKGs were eligible for analysis. 701 patients were included and split into “controlled” and “uncontrolled” at baseline (first PKG), based on predefined cutoff scores for BKS (26) or DKS (5); for FDS, a normal range was defined, above or below which patients were considered uncontrolled. The Mann-whitey U test was used for analysis.

Results: For those patients featuring scores considered “uncontrolled” (BKS high, DKS high, FDS low or high) at baseline, statistically and clinically significant improvements, on average, were recorded for that score in their second PKG in all 4 subgroups (p<0.001). Improved scores were seen in 80% (FDS low),74% (FDS high), 70% (high DKS), and 73% (high BKS) of uncontrolled patients, respectively, in their 2nd PKG.

Conclusions: The analysis suggests that adding a PKG to a PD patient’s therapy management may significantly improve patient PD scores over time. This is important as, due to natural PD progression, one would expect PKG symptom scores to deteriorate over time. Other potential PKG benefits were not part of this analysis.

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/objective-data-in-parkinsons-disease-therapy-management-a-retrospective-analysis-of-the-parkinsons-kinetigraph-pkg-database/